Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Pulse Biosciences, Inc.NASDAQ: PLSE

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $254K fell 7.0% year over year, ahead of the -9.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.4% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Depreciation & amortization amounted to 306.0% of revenue in FY2025.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.0% holds above the trailing-twelve-month pace of -9.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$254K-0.4% QoQ
Last fiscal yearDec 2025
$1.07M-9.1% YoY
LTMJun 2026
$1.02M-9.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.0%——
1 year-9.1%——
3-year CAGR-7.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.07M USD
Year-over-year change
-9.1%
4-year CAGR
-1.7%

Depreciation & Amortization vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.9% is the 6th highest of 11, against a peer median of -8.4%.
  • Depreciation & amortization amounts to 86.4% of revenue for PLSE, versus a peer median of 6.4%.
PLSE Competitors
Depreciation & Amortization for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OPKOPKO Health, Inc.LTM Mar 2026$90.34M USD-5.7%-5.5%15.5%
IMTXImmatics N.V.LTM Mar 2026€12.05M EUR-2.4%+19.6%32.3%
STAASTAAR Surgical CompanyLTM Apr 2026$8.6M USD+7.6%+22.6%3.0%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$8.22M USD-14.7%—9.8%
NVCRNovoCure LimitedLTM Mar 2026$6.43M USD+26.3%+11.3%1.0%
BBNXBeta Bionics, Inc.LTM Mar 2026$2.94M USD+26.6%+11.3%2.7%
LFMDLifeMD, Inc.LTM Mar 2026$2.76M USD-127.4%-55.7%1.3%
PLSEPulse Biosciences, Inc.LTM Jun 2026$1.02M USD-9.9%-7.5%86.4%
ATAIAtai Beckley Inc.LTM Jun 2026$615K USD-18.1%+82.0%13.7%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$379K USD-11.0%+42.8%19.9%
NKTRNektar TherapeuticsLTM Jun 2026$129K USD-88.2%—0.2%
Peer median (excluding PLSE) —-8.4%+15.4%6.4%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
Deferred Income Tax00000
Stock-Based Compensation14.6M5.19M7.18M13.59M21.46M
Change in Working Capital(6.2M)(3.72M)768K2.47M(5.02M)
Accounts Receivables(61K)20K109K48K(274K)
Inventory(5.82M)(2.65M)00(136K)
Accounts Payables1.16M(1.3M)263K(201K)1.13M
Other Working Capital(1.47M)221K396K2.63M(5.74M)
Other Non-Cash Items13K8.66M13K6K1.15M
Operating Cash Flow(54.1M)(47.01M)(33.04M)(36.34M)(54.12M)
Capital Expenditures(437K)(401K)(121K)(125K)(315K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments8M0000
Other Investing Activities0000(20K)
Investing Cash Flow7.56M(401K)(121K)(125K)(335K)
Debt Repayment407K65M000
Common Stock Issued56.7M14.86M16.39M59.65M17.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities62.51M75K(6K)50.49M0
Financing Cash Flow62.69M79.94M16.39M110.14M17.15M
Effect of Forex Changes00000
Net Change in Cash16.15M32.53M(16.77M)73.67M(37.3M)
Free Cash Flow(54.53M)(47.41M)(33.16M)(36.47M)(54.44M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.